Elevation Oncology, Inc.
Elevation Oncology, Inc. (ELEV) Revenue
Annual & quarterly revenue history · segment & region breakdown
ELEV · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsElevation Oncology, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Elevation Oncology, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Elevation Oncology, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Elevation Oncology, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ELEV revenue · 4 questionsELEV's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Elevation Oncology, Inc. SEC filings · GAAP · Elevation Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026